Agios Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Agios Pharmaceuticals generated cash of -$296,062,000, which is more than the previous year. Cash used in financing activities reached the amount of $5,433,000 last year. Net change in cash is therefore -$51,054,000.
Cash Flow
| 2014 | -59.35M | -333.33M | 335.16M |
|---|---|---|---|
| 2015 | -76.94M | 128.30M | 6.37M |
| 2016 | 38.56M | -119.35M | 169.77M |
| 2017 | -285.23M | -57.90M | 285.11M |
| 2018 | -304.42M | -273.82M | 546.02M |
| 2019 | -370.62M | 91.44M | 289.61M |
| 2020 | -290.75M | 75.74M | 261.51M |
| 2021 | -407.32M | 1.24B | -765.76M |
| 2022 | -309.47M | 243.26M | 2.35M |
| 2023 | -296.06M | 239.57M | 5.43M |
AGIO Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 139.25M | 203.12M | 127.43M | 80.93M | 70.50M | 102.72M | 160.75M | 71.76M | 14.03M | 71.56M |
Operating activities | ||||||||||
Net income | -352.08M | -231.80M | -356.51M | -327.37M | -411.47M | -346.02M | -314.67M | -198.47M | -117.73M | -53.50M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 6.62M | 8.56M | 9.24M | 9.98M | 8.08M | 7.17M | 6.43M | 5.70M | 3.34M | 1.36M |
Stock-based compensation expense | 44.76M | 49.29M | 53.50M | 61.60M | 72.37M | 73.35M | 47.80M | 42.08M | 31.96M | 11.50M |
| Deferred income tax benefit | 44.76M | 49.29M | 53.50M | 61.60M | 72.37M | 73.35M | 47.80M | 42.08M | 31.96M | 11.50M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -604K | -2.20M | -4.37M | -10.06M | -3.61M | -6.10M | 1.21M | 3.33M | -1.73M | -6.01M |
Inventories | -10.58M | -8.49M | 4.37M | -7.36M | -6.46M | -869K | -2.07M | 14.43M | -3.17M | 19K |
Accounts payable | -8.73M | 3.43M | 1.86M | 5.88M | 3.71M | -5.48M | 5.32M | 3.50M | 4.21M | 7.57M |
Cash generated by operating activities | -296.06M | -309.47M | -407.32M | -290.75M | -370.62M | -304.42M | -285.23M | 38.56M | -76.94M | -59.35M |
Investing activities | ||||||||||
Purchases Of Investments | -417.93M | -1.03B | -1.37B | -557.03M | -488.56M | -933.32M | -688.70M | -506.06M | -353.17M | -837.21M |
Investments In Property Plant And Equipment | -999K | -4.88M | -5.74M | -14.90M | -12.17M | -6.98M | -4.62M | -9.91M | -20.16M | -2.21M |
Acquisitions Net | 0 | 132.74M | 0 | 803K | -103.46M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 239.57M | 243.26M | 1.24B | 75.74M | 91.44M | -273.82M | -57.90M | -119.35M | 128.30M | -333.33M |
Financing activities | ||||||||||
Common Stock Issued | 5.43M | 2.68M | 37.29M | 11.31M | 277.20M | 516.20M | 270.25M | 162.15M | 6.37M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -802.48M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -331K | -578K | -336K | -113K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 5.43M | 2.35M | -765.76M | 261.51M | 289.61M | 546.02M | 285.11M | 169.77M | 6.37M | 335.16M |
Net Change In Cash | -51.05M | -63.86M | 75.69M | 46.50M | 10.42M | -32.22M | -58.03M | 88.99M | 57.73M | -57.52M |
Cash at end of period | 88.20M | 139.25M | 203.12M | 127.43M | 80.93M | 70.50M | 102.72M | 160.75M | 71.76M | 14.03M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |